{
  "citations" : [
    {
      "id" : 7283333,
      "title" : "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "_sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
      "authors" : [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "crossReferences" : [
        {
          "id" : 769250885,
          "resource" : "PubMed",
          "resourceId" : "21412232",
          "_url" : "https://www.ncbi.nlm.nih.gov/pubmed/21412232",
          "version" : 0
        },
        {
          "id" : 1449247827,
          "resource" : "DOI",
          "resourceId" : "10.1038/clpt.2011.34",
          "_url" : "http://dx.doi.org/10.1038%2Fclpt.2011.34",
          "version" : 0
        }
      ],
      "day" : -1,
      "hasKeyword" : true,
      "journal" : "Clinical pharmacology and therapeutics",
      "meshTerms" : [
        "Animals",
        "Aryl Hydrocarbon Hydroxylases",
        "Cytochrome P-450 CYP2C9",
        "Drug Administration Schedule",
        "Drug-Related Side Effects and Adverse Reactions",
        "Humans",
        "Pharmaceutical Preparations",
        "Pharmacogenetics",
        "Practice Guidelines as Topic"
      ],
      "month" : 5,
      "nonHuman" : false,
      "objCls" : "Literature",
      "page" : "662-73",
      "pediatric" : false,
      "pgkbPublication" : false,
      "pubDate" : "2011-05-01T00:00:00-07:00",
      "pubmedMeshTerms" : [],
      "summary" : "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",
      "terms" : [],
      "type" : "Literature",
      "version" : 4,
      "volume" : "89",
      "year" : 2011
    }
  ],
  "guideline" : {
    "objCls" : "Guideline Annotation",
    "id" : "PA166104976",
    "name" : "Annotation of DPWG Guideline for paroxetine and CYP2D6",
    "alternateDrugAvailable" : true,
    "cancerGenome" : false,
    "crossReferences" : [],
    "dosingInformation" : false,
    "hasTestingInfo" : true,
    "history" : [
      {
        "id" : 1183704513,
        "date" : "2011-08-10T00:00:00-07:00",
        "type" : "Create",
        "version" : 0
      },
      {
        "id" : 1450415003,
        "date" : "2019-05-23T13:52:15.463-07:00",
        "description" : "Annotation current with November 2018 DPWG Guideline release",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450821021,
        "date" : "2019-10-07T18:04:31.410-07:00",
        "description" : "No changes based on August 2019 guideline",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450956392,
        "date" : "2020-01-31T13:44:22.058-08:00",
        "description" : "Updated link to 2011 DPWG methods",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1450963740,
        "date" : "2020-02-11T07:09:26.873-08:00",
        "description" : "Fixed links to 2018 guideline pdfs.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451431322,
        "date" : "2021-05-04T00:00:00-07:00",
        "description" : "Added extended dosing",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451632902,
        "date" : "2022-01-03T15:13:08.953-08:00",
        "description" : "Added DPWG SSRI guideline publication.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451704241,
        "date" : "2022-03-03T16:33:33.575-08:00",
        "description" : "Annotation current with May 2021 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451707400,
        "date" : "2022-03-08T10:10:59.582-08:00",
        "description" : "Added information about preemptive genotyping",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451732881,
        "date" : "2022-03-28T09:57:47.620-07:00",
        "description" : "Annotation current with February 2022 DPWG guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1451733440,
        "date" : "2022-03-28T14:59:33.184-07:00",
        "description" : "Updated link to testing guidance page",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451741501,
        "date" : "2022-04-05T11:17:14.412-07:00",
        "description" : "Added testing guidance tag",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1451884488,
        "date" : "2022-09-16T11:02:58.348-07:00",
        "description" : "Fixed link to gene information document and added explanatory note",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084390,
        "date" : "2023-04-28T18:51:44.363-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084411,
        "date" : "2023-04-28T18:51:57.811-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084432,
        "date" : "2023-04-28T18:52:08.017-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084453,
        "date" : "2023-04-28T18:52:19.806-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084474,
        "date" : "2023-04-28T18:52:49.151-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084495,
        "date" : "2023-04-28T18:53:07.334-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084516,
        "date" : "2023-04-28T18:53:23.380-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084537,
        "date" : "2023-04-28T18:53:40.996-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084558,
        "date" : "2023-04-28T18:54:03.549-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084579,
        "date" : "2023-04-28T18:56:19.982-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452084610,
        "date" : "2023-04-28T19:05:03.352-07:00",
        "description" : "Updated allele function assignment",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452146543,
        "date" : "2023-07-03T13:40:15.886-07:00",
        "description" : "Annotation current with May 2023 DPWG Guideline release",
        "type" : "Note",
        "version" : 0
      },
      {
        "id" : 1452408400,
        "date" : "2024-03-14T10:34:21.183-07:00",
        "description" : "Updated links for risk analysis pdf and preemptive testing page.",
        "type" : "Update",
        "version" : 0
      },
      {
        "id" : 1452413461,
        "date" : "2024-03-19T11:13:27.301-07:00",
        "description" : "Added alternative drug tag.",
        "type" : "Update",
        "version" : 0
      }
    ],
    "literature" : [
      {"id":15126562,"title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.","_sameAs":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553948","crossReferences":[{"id":1452680280,"resource":"PubMed Central","resourceId":"PMC9553948","_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553948"},{"id":1451632760,"resource":"PubMed","resourceId":"34782755","_url":"https://www.ncbi.nlm.nih.gov/pubmed/34782755"},{"id":1451632761,"resource":"DOI","resourceId":"10.1038/s41431-021-01004-7","_url":"http://dx.doi.org/10.1038%2Fs41431-021-01004-7"}],"objCls":"Literature","pubDate":"2022-10-01T00:00:00-07:00","terms":[{"id":1451577480,"resource":"PGx Paper Types","term":"Implementation","termId":"pgxPaperTypes:1451577480"}],"type":"Literature"},
      {"id":7283333,"title":"Pharmacogenetics: from bench to byte--an update of guidelines.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/21412232","crossReferences":[{"id":769250885,"resource":"PubMed","resourceId":"21412232","_url":"https://www.ncbi.nlm.nih.gov/pubmed/21412232"},{"id":1449247827,"resource":"DOI","resourceId":"10.1038/clpt.2011.34","_url":"http://dx.doi.org/10.1038%2Fclpt.2011.34"}],"objCls":"Literature","pubDate":"2011-05-01T00:00:00-07:00","terms":[],"type":"Literature"},
      {"id":15103288,"title":"Dutch Pharmacogenetics Working Group Guidelines August 2019","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","crossReferences":[{"id":1450815695,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_August_2019.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"},
      {"id":15102465,"title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","_sameAs":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","crossReferences":[{"id":1450415575,"resource":"URL","resourceId":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf","_url":"https://api.pharmgkb.org/v1/preview/download/file/attachment/DPWG_November_2018.pdf"}],"objCls":"Literature","terms":[],"type":"Literature"}
    ],
    "otherPrescribingGuidance" : false,
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [],
    "relatedChemicals" : [
      {
        "objCls" : "Chemical",
        "id" : "PA450801",
        "name" : "paroxetine",
        "version" : 15
      }
    ],
    "relatedGenes" : [
      {
        "objCls" : "Gene",
        "id" : "PA128",
        "symbol" : "CYP2D6",
        "name" : "cytochrome P450 family 2 subfamily D member 6",
        "version" : 7891
      }
    ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1447982034,
      "html" : "<p>Select an alternative drug rather than paroxetine for CYP2D6 ultrarapid metabolizer patients.</p>\n",
      "version" : 1
    },
    "terms" : [],
    "textMarkdown" : {
      "id" : 1447982033,
      "html" : "<p>Read more about how PharmGKB <a href=\"/page/dpwgMapping\">curates DPWG guidelines</a> using extra information provided by DPWG to enable the interactive genotype tool above.</p>\n<h3 id=\"dutch-pharmacogenetics-working-group-dpwg-guideline-for-the-gene-drug-interaction-between-cyp2c19-and-cyp2d6-and-ssris-european-journal-of-human-genetics-2021\">Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs. European journal of human genetics (2021)</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group published a paper with the guidelines as per the November 2018 update and further details on the assessed literature [Article:<a href=\"/pmid/34782755\">34782755</a>].</p>\n<h3 id=\"november-2018-update\">November 2018 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for paroxetine based on CYP2D6 genotype. They recommend paroxetine be avoided in patients who are CYP2D6 ultrarapid metabolizers (UMs). There are no recommendations for patients who are CYP2D6 intermediate metabolizers (IMs) or poor metabolizers (PMs).</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_November_2018.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_November_2018.pdf\">Dutch guidelines November 2018 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP2D6 UM</td>\n<td>paroxetine</td>\n<td>Efficacy will probably be lacking. The genetic variation increases the conversion of paroxetine.</td>\n<td>It is not possible to offer substantiated advice for dose adjustment based on the literature. Avoid paroxetine. Antidepressants that are not metabolised by CYP2D6, or to a lesser extent, include for example citalopram or sertraline.</td>\n</tr>\n<tr>\n<td>CYP2D6 IM</td>\n<td>paroxetine</td>\n<td>The plasma concentration of paroxetine can increase as a result of the reduced activity of CYP2D6. However, studies did not find any clinical effects.</td>\n<td>NO action is needed for this gene-drug interaction.</td>\n</tr>\n<tr>\n<td>CYP2D6 PM</td>\n<td>paroxetine</td>\n<td>The plasma concentration of paroxetine can increase as a result of the reduced activity of CYP2D6. However, studies did not find any clinical effects.</td>\n<td>NO action is needed for this gene-drug interaction.</td>\n</tr>\n</tbody>\n</table>\n<p><a download=\"DPWG_CYP2D6_paroxetine_1563-1564-1565.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_CYP2D6_paroxetine_1563-1564-1565.pdf\">Read for more information about this recommendation</a>, <a download=\"CYP2D6.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/CYP2D6.pdf\">Read about gene information from DPWG</a></p>\n<h4 id=\"preemptive-genotyping\">Preemptive genotyping</h4>\n<p>Excerpts from the <a download=\"DPWG_CYP2D6_paroxetine_1563-1564-1565.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_CYP2D6_paroxetine_1563-1564-1565.pdf\">DPWG risk analysis document</a> for paroxetine and CYP2D6:</p>\n<blockquote class=\"blockquote\">\n<p>The Dutch Pharmacogenetics Working Group considers genotyping before starting paroxetine to be potentially beneficial for drug efficacy. Genotyping can be considered on an individual patient basis. If, however, the genotype is available, the Dutch Pharmacogenetics Working Group recommends adhering to the gene-drug guideline.</p>\n</blockquote>\n<p><a href=\"/page/dpwgPreemptiveGenotyping\">Read more about how DPWG assigns their recommendations for preemptive genotyping.</a></p>\n<h3 id=\"2011-guideline\">2011 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for paroxetine based on CYP2D6 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They suggest using an alternative drug for ultra metabolizers.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Phenotype (Genotype)</th>\n<th>Therapeutic Dose Recommendation</th>\n<th>Level of Evidence</th>\n<th>Clinical Relevance</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>PM (2 inactive alleles)</td>\n<td>None.</td>\n<td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td>\n<td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td>\n</tr>\n<tr>\n<td>IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele)</td>\n<td>None.</td>\n<td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td>\n<td>Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S).</td>\n</tr>\n<tr>\n<td>UM (gene duplication in absence of inactive or decreased activity alleles)</td>\n<td>Insufficient data to allow calculation of dose adjustment.  Select alternative drug (e.g., citalopram, sertraline).</td>\n<td>Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints.</td>\n<td>Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10<sup>9</sup>/l; leucopenia 2.0-3.0x10<sup>9</sup>/l; thrombocytopenia 50-75x10<sup>9</sup>/l.</td>\n</tr>\n</tbody>\n</table>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele Type</th>\n<th>Alleles</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>active</td>\n<td>*1, *2, *33, *35</td>\n</tr>\n<tr>\n<td>decreased activity</td>\n<td>*9, *10, *17, *29, *36, *41</td>\n</tr>\n<tr>\n<td>inactive</td>\n<td>*3-*8, *11-*16, *19-*21, *38, *40, *42</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>*See <a href=\"http://www.pharmgkb.org/page/dpwg\">Methods </a> or [Article:<a href=\"/pmid/18253145\">18253145</a>] for definition of &quot;good quality.&quot;</li>\n<li>S: statistically significant difference.</li>\n</ul>\n",
      "version" : 18
    },
    "version" : 35
  }
}